'Next Science’s initial sales focus will be the US orthopaedic surgery market of 5.3M surgeries per year in 20104; a market opportunity of over $1B per annum.'
$189 to stop infections in patients seems like a no brainer to me.
Of course the patient will probably end nd up paying $1,000+ in the US healthcare system!
Ann: XPerience No Rinse Antimicrobial Solution cleared by FDA, page-2
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $72.92M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 25.5¢ | 25.0¢ | $4.813K | 18.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 18954 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 23171 | 4 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
25.0¢ |
Change
-0.005 ( 1.96 %) |
||||
| Open | High | Low | Volume | ||
| 25.0¢ | 25.5¢ | 25.0¢ | 17323 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| NXS (ASX) Chart |